Please login to the form below

Not currently logged in
Email:
Password:

Cabometyx

This page shows the latest Cabometyx news and features for those working in and with pharma, biotech and healthcare.

European Commission approves Opdivo plus Cambometyx for advanced kidney cancer

European Commission approves Opdivo plus Cambometyx for advanced kidney cancer

Twice as many patients responded to Opdivo plus Cabometyx compared to Sutent – 55.7% and 27.1%, respectively. ... Opdivo/Cabometyx was also associated with a disease control rate of 88.2% versus 69.9% with Sutent.

Latest news

More from news
Approximately 9 fully matching, plus 10 partially matching documents found.

Latest Intelligence

  • Charting a course for expansion Charting a course for expansion

    The February deal, which gives Ipsen commercialisation and development rights outside the US, has seen Cabometyx take off rapidly. ... It showed that Cabometyx can decrease the rate of disease progression or death by 31% in advanced renal cell carcinoma

More from intelligence
Approximately 1 fully matching, plus 0 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
3 Monkeys Zeno

3 Monkeys Zeno is an award winning global creative communications consultancy – home to a collective of creative and strategic...

Latest intelligence

Cervical Cancer Prevention Month
In this first 2022 blog, the Innovative Trials' Equality & Diversity committee will be looking at raising awareness around Cervical Cancer...
6 critical success factors for flawless execution of a rapid first commercial launch
Annemarie Armstrong, Executive Vice President, US Head of Client Services, shares the key considerations for launching a first commercial product, particularly on a rapid timeline....
Hybrid working: Insights and tips for success
Porterhouse Medical has thrived by embracing a hybrid approach to work. Our article looks at hybrid working and provides some tips for success...